Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLG vs ATG on Immune Reconstitution After Allo-HSCT for Malignant Hematologic Diseases
NCT06895538Phase 3Recruiting
- Sponsor
- Peking University First Hospital
- Start
- May 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 3, open-label trial of grafalon in leukemia, myelodysplastic syndrome (MDS) and lymphoma (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Incidence of viral infections after hematopoietic stem cell transplantation at 1 year. Started May 2025; status: recruiting.
02
Drugs
grafalon
03
Conditions
leukemiamyelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT06895538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895538.